HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

RA 25

structure in first source
Also Known As:
RA-25; RA25 cpd
Networked: 28 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Calabrese, Cassandra: 1 article (11/2021)
2. Calabrese, Leonard H: 1 article (11/2021)
3. Hajj-Ali, Rula A: 1 article (11/2021)
4. Jin, Yuxuan: 1 article (11/2021)
5. Kirchner, Elizabeth: 1 article (11/2021)
6. Lenfant, Tiphaine: 1 article (11/2021)
7. Baraliakos, Xenofon: 1 article (11/2021)
8. Braun, Jürgen: 1 article (11/2021)
9. Kiltz, Uta: 1 article (11/2021)
10. Pudelko, Jan-Clemens: 1 article (11/2021)

Related Diseases

1. Pain (Aches)
01/01/2017 - " approved dose of certolizumab pegol, 200 mg every other week, produced clinically important improvements at 24 weeks for the following outcomes:- American College of Rheumatology (ACR) 50% improvement (pain, function and other symptoms of RA): 25% absolute improvement (95% confidence interval (CI) 20% to 33%); number need to treat for an additional beneficial outcome (NNTB) of 4 (95% CI 3 to 5); risk ratio (RR) 3.80 (95% CI 2.42 to 5.95), 1445 participants, 5 studies.- The Health Assessment Questionnaire (HAQ): -12% absolute improvement (95% CI -9% to -14%); NNTB of 8 (95% CI 7 to 11); mean difference (MD) - 0.35 (95% CI -0.43 to -0.26; 1268 participants, 4 studies) (scale 0 to 3; lower scores mean better function).- Proportion of participants achieving remission (Disease Activity Score (DAS) < 2.6) absolute improvement 10% (95% CI 8% to 16%); NNTB of 8 (95% CI 6 to 12); risk ratio (RR) 2.94 (95% CI 1.64 to 5.28), 2420 participants, six studies.- Radiological changes: erosion score (ES) absolute improvement -0.29% (95% CI -0.42% to -0.17%); NNTB of 6 (95% CI 4 to 10); MD -0.67 (95% CI -0.96 to -0.38); 714 participants, two studies (scale 0 to 230), but not a clinically important difference.-Serious adverse events (SAEs) were statistically but not clinically significantly more frequent for certolizumab pegol (200 mg every other week) with an absolute rate difference of 3% (95% CI 1% to 4%); number needed to treat for an additional harmful outcome (NNTH) of 33 (95% CI 25 to 100); Peto odds ratio (OR) 1.47 (95% CI 1.13 to 1.91); 3927 participants, nine studies.There"
2. Rheumatoid Arthritis
3. Systemic Lupus Erythematosus (Libman-Sacks Disease)
4. Osteoarthritis
5. Arthritis (Polyarthritis)

Related Drugs and Biologics

1. Certolizumab Pegol
2. cyclo(Arg-Pro) (CI 4)
3. amsonic acid (DAS)
4. ametantrone (HAQ)
5. Autoantibodies
6. Biosimilar Pharmaceuticals
7. Vitamin B 12 (Cyanocobalamin)
8. Ribosomal Proteins (Ribosomal Protein)
9. Proteins (Proteins, Gene)
10. Iron

Related Therapies and Procedures

1. Joint Prosthesis
2. Arthroplasty